Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis

Seoul National University Hospital11 enrolled

Overview

Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis. This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled patients will be 11

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Takayasu's Arteritis

Interventions

remicade (anti tumor necrosis factor inhibitor)DRUG

single arm:remicade treatment group

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * active takayasu's arteritis Exclusion Criteria: * active Tuberculosis * Liver function abnormality * heart failure ( New York Heart Association III - IV) * patients were not consented

Locations (1)

Seoul National University Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

remission induction at 30 weeks

Time frame: 30 weeks

Central Contacts

Sang Jin Lee, MD

CONTACT

82-10-8623-2648 dream1331@naver.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.